drugset / Trial / NCT01581034

Effect of PADMA 28 on Endothelial Function, Autonomic Nervous System and Biomarkers in Patients With Coronary Artery Disease

NCT01581034 ↗

Phase 2 Completed 80 enrolled Insel Gruppe AG, University Hospital Bern
RandomizedParallel-groupQuadruple-blindSupportive care

Summary

This randomized, placebo-controlled, double-blinded trial investigates the effect of a 6 week intake of PADMA 28 on the endothelial function, biomarkers and the autonomic nervous systems in patients with coronary artery disease. The investigators hypothesize that PADMA 28 has a beneficial effect on endothelial function, arterial stiffness, the autonomic nervous systen and the blood inflammatory markers in patients with coronary artery disease compared to placebo treatment.

Timeline

Start
2012-04
Primary completion
2013-05
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator PADMA 28 Unknown 806 mg Oral